SCHEMBL14045978

SCHEMBL14045978

O=C(Nc1ccc(F)cc1)Nc1ccc(N2C=CCC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
TAAR1 Q96RJ0 1/20 0.51
NPC1 O15118 8/20 0.48
RAB9A P51151 8/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
HTT P42858 4/20 0.48
POLB P06746 2/20 0.48
EPHX2 P34913 2/20 0.47
MAPT P10636 4/20 0.46
RECQL P46063 2/20 0.46
EPHX1 P07099 1/20 0.46
FPR2 P25090 1/20 0.45
MAPK1 P28482 3/20 0.45
XBP1 P17861 1/20 0.45
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3070329 0.75 KMT2A (0.76) KMT2AMEN1TAAR1NPC1RAB9A
SCHEMBL28380433 0.73 LMNA (0.31) MAPTL3MBTL1
SCHEMBL4922234 0.73 MAPT (0.73) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL28217503 0.72 ALDH1A1 (0.39) KMT2ANPC1RAB9AHTTMAPT
SCHEMBL10356831 0.71 KMT2A (0.44) KMT2AMEN1TAAR1NPC1RAB9A
SCHEMBL4920587 0.70 MEN1 (0.56) KMT2AMEN1TAAR1NPC1RAB9A
SCHEMBL13973362 0.70 ALDH1A1 (0.39) ALDH1A1
SCHEMBL4912541 0.69 KMT2A (0.61) KMT2AMEN1TAAR1NPC1RAB9A
SCHEMBL4917143 0.69 KMT2A (1.00) KMT2AMEN1TAAR1NPC1RAB9A
SCHEMBL11056635 0.68 SMN1; SMN2 (0.74) KMT2AMEN1TAAR1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R KMT2A 1905/4885MEN1 4843/4885TAAR1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.